PH12013502568B1 - Anti-psgl-1 antibodies and uses thereof - Google Patents

Anti-psgl-1 antibodies and uses thereof

Info

Publication number
PH12013502568B1
PH12013502568B1 PH1/2013/502568A PH12013502568A PH12013502568B1 PH 12013502568 B1 PH12013502568 B1 PH 12013502568B1 PH 12013502568 A PH12013502568 A PH 12013502568A PH 12013502568 B1 PH12013502568 B1 PH 12013502568B1
Authority
PH
Philippines
Prior art keywords
antibodies
psgl
cells
polynucleotides
kits
Prior art date
Application number
PH1/2013/502568A
Other languages
English (en)
Other versions
PH12013502568A1 (en
Inventor
Stefan Bassarab
Barbara Enenkel
Patrick Garidel
Tobias Litzenburger
Heidrun Schott
Sanjaya Singh
Original Assignee
Abgenomics Coop U A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47357432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12013502568(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abgenomics Coop U A filed Critical Abgenomics Coop U A
Publication of PH12013502568A1 publication Critical patent/PH12013502568A1/en
Publication of PH12013502568B1 publication Critical patent/PH12013502568B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PH1/2013/502568A 2011-06-13 2012-06-12 Anti-psgl-1 antibodies and uses thereof PH12013502568B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161496249P 2011-06-13 2011-06-13
PCT/US2012/042068 WO2012174001A1 (en) 2011-06-13 2012-06-12 Anti-psgl-1 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
PH12013502568A1 PH12013502568A1 (en) 2014-01-27
PH12013502568B1 true PH12013502568B1 (en) 2018-08-10

Family

ID=47357432

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2013/502568A PH12013502568B1 (en) 2011-06-13 2012-06-12 Anti-psgl-1 antibodies and uses thereof

Country Status (21)

Country Link
US (4) US20130209449A9 (https=)
EP (2) EP2718325A4 (https=)
JP (1) JP6180408B2 (https=)
KR (1) KR102103036B1 (https=)
CN (3) CN108892726A (https=)
AU (1) AU2012271845B2 (https=)
BR (1) BR112013031892A2 (https=)
CA (1) CA2838952C (https=)
CL (1) CL2013003570A1 (https=)
CO (1) CO6940376A2 (https=)
EC (1) ECSP14013132A (https=)
IL (2) IL229844B (https=)
MX (1) MX358447B (https=)
NZ (1) NZ619524A (https=)
PH (1) PH12013502568B1 (https=)
RU (1) RU2650817C2 (https=)
SG (1) SG10201604767TA (https=)
TW (1) TWI643872B (https=)
UA (1) UA114712C2 (https=)
WO (1) WO2012174001A1 (https=)
ZA (1) ZA201400209B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
UY28886A1 (es) 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
ES2655833T3 (es) 2004-05-11 2018-02-21 AbGenomics Coöperatief U.A. Epítopos que inducen la muerte de células T
EP2718325A4 (en) 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
PT3166636T (pt) * 2014-07-08 2021-06-29 Sanford Burnham Med Res Inst Moduladores de psgl-1 e utilizações dos mesmos
IL260289B (en) * 2016-01-08 2022-08-01 Bioalliance Cv Tetravalent anti-psgl-1 antibodies and uses thereof
WO2017214941A1 (zh) * 2016-06-16 2017-12-21 毛侃琅 一种提升SelP基因表达水平的慢病毒载体及其应用
KR20250159733A (ko) 2017-01-11 2025-11-11 브리스톨-마이어스 스큅 컴퍼니 Psgl-1 길항제 및 그의 용도
TWI787230B (zh) 2017-01-20 2022-12-21 法商賽諾菲公司 抗ＴＧＦ-β抗體及其用途
TWI832600B (zh) * 2017-01-20 2024-02-11 美商健臻公司 骨靶向抗體
PE20250933A1 (es) 2017-03-14 2025-04-02 Five Prime Therapeutics Inc Anticuerpos de union a vista a ph acido
BR112020019083A2 (pt) 2018-03-21 2020-12-29 Five Prime Therapeutics, Inc. Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
PE20210687A1 (es) 2018-07-11 2021-04-08 Bristol Myers Squibb Co Anticuerpos de union a vista a ph acido
CN112740043A (zh) 2018-07-20 2021-04-30 皮埃尔法布雷医药公司 Vista受体
JP7317379B2 (ja) * 2019-01-04 2023-07-31 国立大学法人京都大学 潰瘍性大腸炎及び原発性硬化性胆管炎の検査方法
CA3141334A1 (en) * 2019-06-04 2020-12-10 Verseau Therapeutics, Inc. Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
KR20230015365A (ko) * 2020-05-22 2023-01-31 포르미콘 아게 Ace2 융합 단백질 및 이의 용도
CN113667015B (zh) * 2021-08-20 2022-10-11 北京康特泊瑞生物医药科技股份公司 靶向psgl-1蛋白的抗体及其用途
US12290565B2 (en) 2021-11-17 2025-05-06 Altrubio Inc. Methods of using anti-PSGL-1 antibodies in combination with JAK inhibitors to treat T-cell mediated inflammatory diseases or cancers
AU2023343549A1 (en) * 2022-09-13 2025-03-20 Tetherex Pharmaceuticals Corporation Antibodies, compositions, and methods of treatment
WO2025106784A1 (en) * 2023-11-17 2025-05-22 Altrubio Inc. Anti-psgl-1 antibodies and uses thereof

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5378464A (en) 1989-03-08 1995-01-03 Board Of Regents Of The University Of Oklahoma Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140
US5690933A (en) 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US5709859A (en) 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US6124267A (en) 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US5972625A (en) 1991-05-06 1999-10-26 The Regents Of The University Of California Assays for inhibitors of leukocyte adhesion
ES2131107T3 (es) 1992-03-17 1999-07-16 Novartis Ag Anticuerpos obtenidos mediante ingenieria genetica.
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US5843707A (en) 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
WO1994014836A1 (en) 1992-12-18 1994-07-07 Centocor, Inc. Peptide inhibitors of selectin binding
DE69415154T2 (de) 1993-01-25 1999-07-29 Dana-Farber Cancer Institute, Inc., Boston, Mass. Chimäre selektine erhältlich durch domänenaustauch und ihre verwendungen
WO1995014787A1 (en) 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
KR100523506B1 (en) 1995-08-03 2005-10-24 Peptide and O-glycan inhibitors of selectin mediated inflammation
US6348581B1 (en) 1996-10-31 2002-02-19 The Dow Chemical Company High affinity humanized anti-TAG-72 monoclonalantibodies
WO1999043353A2 (en) 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Combination anti-selectin and immunosuppressant therapy
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
CA2347119A1 (en) 1998-10-30 2000-05-11 Genetics Institute, Inc. Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US6696620B2 (en) 2000-05-02 2004-02-24 Epicyte Pharmaceutical, Inc. Immunoglobulin binding protein arrays in eukaryotic cells
DE60118362T2 (de) 2000-05-19 2007-05-24 The Center for Blood Research, Inc., Boston VERFAHREN ZUR BEHANDLUNG VON HÄMOSTATISCHEN STÖRUNGEN DURCH LöSLICHES P-SELECTIN
EP1325123A4 (en) 2000-09-12 2004-07-21 Inst Genetics Llc STENOSE- OR RESEARCH INHIBITION BY P-SELECTIN ANTAGONISTS
US20040001839A1 (en) 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040002450A1 (en) 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
EP1406930A4 (en) 2000-12-29 2007-01-10 Savient Pharmaceuticals Inc "ISOLATED MOLECULES WITH SULFATED GROUPING CONTAINING EPITOPES, ANTIBODIES AGAINST SUCH EPITOPES AND USES THEREOF"
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US6884619B2 (en) 2001-07-17 2005-04-26 Yale University Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
WO2004003166A2 (en) 2002-07-01 2004-01-08 Savient Pharmaceuticals, Inc. Antibodies and uses thereof
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
CA2531283A1 (en) 2003-06-30 2005-01-20 Bio-Technology General (Israel) Ltd. Specific human antibodies
CN1922316B (zh) * 2003-12-25 2011-03-23 协和发酵麒麟株式会社 抗cd40抗体突变体
US7544487B2 (en) * 2004-02-13 2009-06-09 Immunomedics, Inc. Fusion proteins containing recombinant cytotoxic RNAses
PT1737891E (pt) * 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
UY28886A1 (es) * 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
ES2655833T3 (es) 2004-05-11 2018-02-21 AbGenomics Coöperatief U.A. Epítopos que inducen la muerte de células T
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
TWI380996B (zh) * 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
EP2046833B9 (en) * 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
SI2132230T1 (sl) * 2007-03-22 2014-07-31 Genentech, Inc. Apoptotska protitelesa, ki veĹľejo membransko-vezan IgE
ES2593484T3 (es) * 2007-03-29 2016-12-09 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
JP6071165B2 (ja) * 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
CA2687896A1 (en) 2007-06-05 2008-12-18 Yale University Antibody directed against the d4 ig-like domain of the kit receptor
CA2697612A1 (en) 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Anti-igf-1r antibodies and uses thereof
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US8092804B2 (en) * 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
US20110086366A1 (en) * 2008-02-22 2011-04-14 Genmab A/S Methods for assessing the risk of adverse events upon treatment with igg4 antibodies
US7833530B2 (en) * 2008-05-15 2010-11-16 Selexys Pharmaceuticals Corporation Methods of inhibiting the PSGL-1-mediated adhesion and chemokine-mediated migration with PSGL-1-specific antibodies
US20100233157A1 (en) * 2009-03-12 2010-09-16 Osorio Lyda M Human antibodies against human fas and their use
BR112012007875A2 (pt) 2009-07-31 2016-11-22 Medarex Inc anticorpos totalmente humanos para btla
EP2718325A4 (en) 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
AU2015277100A1 (en) 2014-06-20 2017-02-02 Abgenomics International Inc. HER2 antibody-drug conjugates

Also Published As

Publication number Publication date
MX358447B (es) 2018-08-21
IL287270A (en) 2021-12-01
CA2838952C (en) 2020-11-24
ECSP14013132A (es) 2015-04-30
JP2014519524A (ja) 2014-08-14
KR20140066153A (ko) 2014-05-30
IL229844B (en) 2022-02-01
TWI643872B (zh) 2018-12-11
TW201302791A (zh) 2013-01-16
US20210395383A1 (en) 2021-12-23
CN103732626A (zh) 2014-04-16
BR112013031892A2 (pt) 2016-11-22
SG10201604767TA (en) 2016-08-30
KR102103036B1 (ko) 2020-04-22
AU2012271845B2 (en) 2017-07-27
CO6940376A2 (es) 2014-05-09
AU2012271845A1 (en) 2014-01-23
US11897964B2 (en) 2024-02-13
NZ619524A (en) 2016-10-28
US20240124604A1 (en) 2024-04-18
EP3925978A1 (en) 2021-12-22
JP6180408B2 (ja) 2017-08-16
CL2013003570A1 (es) 2014-08-22
CA2838952A1 (en) 2012-12-20
EP2718325A1 (en) 2014-04-16
US20130251708A1 (en) 2013-09-26
RU2650817C2 (ru) 2018-04-17
WO2012174001A1 (en) 2012-12-20
ZA201400209B (en) 2020-05-27
EP2718325A4 (en) 2015-03-11
RU2013158083A (ru) 2015-09-20
CN116063522A (zh) 2023-05-05
US20130011391A1 (en) 2013-01-10
US20130209449A9 (en) 2013-08-15
PH12013502568A1 (en) 2014-01-27
MX2013014814A (es) 2014-07-22
UA114712C2 (uk) 2017-07-25
CN108892726A (zh) 2018-11-27

Similar Documents

Publication Publication Date Title
PH12013502568B1 (en) Anti-psgl-1 antibodies and uses thereof
MY171038A (en) Bispecific antigen binding molecules
MY169358A (en) Bispecific t cell activating antigen binding molecules
PH12015501340A1 (en) Bispecific t cell activating antigen binding molecules
MX2015010843A (es) Moleculas biespecificas de union al antigeno que activan celulas t.
MX2015010350A (es) Moleculas de union a antigeno biespecificas que activan la celula t.
MY184889A (en) T cell activating bispecific antigen binding molecules
MY202917A (en) Bispecific t cell activating antigen binding molecules
MX359854B (es) Anticuerpos anti-cxcr3.
MX2018003631A (es) Moleculas biespecificas de union a antigeno activadoras de celulas t.
MX374906B (es) Nuevos inmunoconjugados
PH12014501108A1 (en) Anti-il-36r antibodies
EA201490636A1 (ru) Сконструированные с помощью рнк t-клетки для лечения злокачественных новообразований
UA116766C2 (uk) Зв'язувальна молекула, яка є біоспецифічною до вcma і cd3
MX349662B (es) Anticuerpos de antigenos antitumorales y metodos de uso.
PH12015500113A1 (en) Anti-kit antibodies and uses thereof
MY175708A (en) Dna antibody constructs and method of using same
MX2014002996A (es) Anticuerpos anti - egfr/anti - igf-1r bisespecificos.
MX2014013676A (es) Uso de moleculas de enlace a la semaforina-4d para promover la neurogenesis despues de la apoplejia.
TH157671A (th) แอนติ-psgl-1 แอนติบอดีและการใช้ของมัน
TN2013000265A1 (en) Anti-cd38 antibodies